

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1 – 15 (Canceled)

Claim 16 (Previously Presented): A liposome comprising a bonded compound containing a polyalkylene glycol moiety bound to the liposome through thioether groups and a separately bonded antibody bound to the liposome through thioether groups, said liposome comprising lipids whose partial component has maleimidated terminal, and wherein an amount of the bonded compound is 15 to 30 mole% based on one mole of the maleimidated lipid, and an amount of the bonded antibody is 1.2 to 2 mg per 100 mg of total lipids that constitute the liposome, and said antibody comprising a GAH antibody.

Claim 17 (Original): The liposome according to claim 16, which is obtained by reacting a maleimide group of the maleimidated lipid with the compound containing a polyalkylene glycol moiety introduced with a thiol group.

Claim 18 (Previously Presented): The liposome according to claim 16, wherein the compound is bonded to a surface of the liposome.

Claim 19 (Previously Presented): The liposome according to claim 16, wherein the polyalkylene glycol is polyethylene glycol.

Claim 20 (Original): The liposome according to claim 19, wherein the compound has two polyethylene glycol groups.

Claim 21 (Previously Presented): The liposome according to claim 20, wherein each polyethylene glycol group has a molecular weight of 2,000 to 7,000 daltons.

Claim 22 (Previously Presented): The liposome according to claim 20, wherein each polyethylene glycol group has a molecular weight of about 5,000 daltons.

Claim 23 (Previously Presented): The liposome according to claim 16, which is a liposome obtained by reacting a liposome having a maleimide group and a sulfur-containing group deriving from the antibody to form a thioether bond.

Claims 24-31 (Canceled)

Claim 32 (Previously Presented): A medicament composition for treatment of cancer comprising the liposome according to claim 16 and a medicament effective for treatment of cancer.

Claim 33 (Previously Presented): The medicament composition according to claim 32, wherein the cancer is stomach cancer or colon cancer.

Claim 34 (Previously Presented): A method for treatment of cancer which comprises administering to a patient the medicament composition according to claim 32.

Claims 35-36 (Canceled)

Claim 37 (Previously Presented): The medicament composition according to claim 32 wherein the medicament comprises doxorubicin.